

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Fulvestrant for the treatment of locally advanced or metastatic breast cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised in any of the submissions.

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified by the Committee.
--

- | |
|---|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group? |
|---|

Fulvestrant is not recommended for the treatment of locally advanced or metastatic breast cancer in any groups of patients. Therefore, the preliminary recommendations do not make it more difficult in practice for a specific group to access fulvestrant compared with other groups.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No barriers to access were identified in question 4.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The summary table of the appraisal consultation document states that no equality issues were raised during the scoping process or identified by the Appraisal Committee.

Approved by Associate Director (name): ...Helen Knight.....

Date: 12/08/2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

The Committee considered a potential equalities issue highlighted during consultation on the appraisal consultation document about the use of fulvestrant for patients unable to swallow oral aromatase inhibitor medication. The Committee was aware that women who are unable to swallow (for example, following a stroke) would be fed using an enteral tube, and that oral medication can also be given by this route. In addition, given that the recommendation did not differentiate between any groups of people, the Committee concluded that its recommendations did not limit access to the

technology for any specific group compared with other groups.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations did not change after consultation. Therefore, the final recommendations do not make it more difficult in practice for a specific group to access fulvestrant compared with other groups.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

No barriers to access were identified in question 2.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues are described in section 4.20 of the final appraisal determination.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 29/11/2011